Epithalon vs Prostatilen
Comparison of Epithalon (Low evidence) and Prostatilen (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Epithalon
Dossier overview
Prostatilen
Dossier overview
Overview
Epithalon and Prostatilen are both studied in the peptide research space.
Epithalon: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan.
Prostatilen: A peptide complex extracted from bovine prostate glands, developed in Russia and registered as a pharmaceutical for prostatitis treatment.
Evidence Comparison
| Aspect | Epithalon | Prostatilen |
|---|---|---|
| Evidence Level | Low | Moderate |
| Human Studies | 5 | 8 |
| Preclinical Studies | 15 | 7 |
| Total Sources | 28 | 18 |
Key Differences
| Aspect | Epithalon | Prostatilen |
|---|---|---|
| Category | Longevity | Hormonal |
| Evidence Strength | Low | Moderate |
| Total Sources | 28 | 18 |
| Human Studies | 5 | 8 |
Summary
- Epithalon: Low evidence with 28 total sources (5 human)
- Prostatilen: Moderate evidence with 18 total sources (8 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.